| Name | BMS-962212 |
|---|---|
| Synonyms |
BMS96221
(S,E)-4-(2-(3-(3-Chloro-2-fluoro-6-(1H-tetrazol-1- yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)- 1,2,3,4-tetrahydroisoquinoline-1-cboxamido)benzoic acid Benzoic acid, 4-[[[(1S)-2-[(2E)-3-[3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl]-1-oxo-2-propen-1-yl]-1,2,3,4-tetrahydro-5-(4-methyl-2-oxo-1-piperazinyl)-1-isoquinolinyl]carbonyl]amino] 4-(2-(3-(3-Chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-ca rboxamido)benzoic acid BMS-962212 (BMS962212) |
| Description | BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C32H28ClFN8O5 |
|---|---|
| Molecular Weight | 659.07 |